文献速递细菌感染、耐药与抗菌药物医院感染防控

快速菌种鉴定联合当日表型药敏对血流感染管理及结局的临床影响

Clinical Impact of Rapid Species Identification From Positive Blood Cultures With Same-day Phenotypic Antimicrobial Susceptibility Testing on the Management and Outcome of Bloodstream Infections.
PubMed 文献 · Clin Infect Dis · 2020-01-01

快速诊断显著缩短了革兰染色至菌种鉴定(中位23 vs 2.2小时)和药敏(中位23 vs 7.4小时)的时间,并缩短至最优治疗和降阶梯治疗时间,但抗菌药物消耗、死亡率、住院时长及艰难梭菌感染发生率无差异。

要点

  • 快速诊断联合ASP可显著缩短菌种鉴定和药敏报告时间。
  • 快速诊断未减少抗菌药物消耗或改善临床结局。
  • ASP联合快速诊断可优化治疗时机但需结合综合管理。

核心结论

  • 使用Accelerate Pheno系统显著缩短了菌种鉴定和药敏时间,以及至最优抗菌治疗的时间,但未影响抗菌药物消耗和临床结局。

主要发现

  • 快速诊断组革兰染色至菌种鉴定中位时间23 vs 2.2小时(P < .001),至药敏中位时间23 vs 7.4小时(P < .001)。
  • 快速诊断组革兰染色至最优治疗中位时间11 vs 7小时(P = .024),至降阶梯治疗中位时间27.8 vs 12小时(P = .019)。
  • 三组在抗菌药物消耗、抗菌治疗时长、死亡率、住院时长和艰难梭菌感染发生率方面无差异。

临床怎么用

  • 快速诊断联合ASP可用于缩短血流感染病原鉴定和药敏报告时间,优化治疗时机,但需结合综合管理以改善抗菌药物使用和结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Timely availability of microbiological results from positive blood cultures is essential to enable early pathogen-directed therapy. The Accelerate Pheno system (ADX) is a novel technology using fluorescence in situ hybridization for rapid species identification (ID) and morphokinetic bacterial analysis for phenotypic antimicrobial susceptibility testing (AST), with promising results. Yet the impact of this technology on clinical management and patient outcome remains unclear. METHODS: We conducted a quasiexperimental before-and-after observational study and analyzed 3 groups with different diagnostic and therapeutic pathways following recent integration of ADX: conventional microbiological diagnostics with and without antimicrobial stewardship program (ASP) intervention, and rapid diagnostics (ADX in addition to conventional standard) with ASP intervention. Primary endpoints were time to adequate, to optimal and to step-down antimicrobial therapy. Secondary endpoints were antimicrobial consumption, in-hospital mortality, length of stay (LOS), and the incidence of Clostridioidesdifficile infection (CDI). RESULTS: Two hundred four patients (conventional diagnostics, n = 64; conventional diagnostics + ASP, n = 68; rapid diagnostics + ASP; n = 72) were evaluated. The use of ADX significantly decreased time from Gram stain to ID (median, 23 vs 2.2 hours, P < .001) and AST (median, 23 vs 7.4 hours, P < .001), from Gram stain to optimal therapy (median, 11 vs 7 hours, P = .024) and to step-down antimicrobial therapy (median, 27.8 vs 12 hours, P = .019). However, groups did not differ in antimicrobial consumption, duration of antimicrobial therapy, mortality, LOS, or incidence of CDI. CONCLUSIONS: Use of ADX significantly reduced time to ID and AST as well as time to optimal antimicrobial therapy but did not affect antimicrobial consumption and clinical outcome.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ehren K, Meißner A, Jazmati N, et al. Clinical Impact of Rapid Species Identification From Positive Blood Cultures With Same-day Phenotypic Antimicrobial Susceptibility Testing on the Management and Outcome of Bloodstream Infections. Clin Infect Dis. 2020. PMID: 31094414. doi:10.1093/cid/ciz406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。